Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The biology of hypomorphic TP53 variants and implications for clinical management.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.

The Journal of clinical investigation·2026
Same author

Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort.

JNCI cancer spectrum·2026
Same author

The impact of breast cancer polygenic risk score disclosure on decisional conflict around risk-reducing mastectomy in women with pathogenic BRCA1/2 variants.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosis.

Molecular cancer research : MCR·2026
Same author

Video Education With Clinical Genetic Testing Coordinators for the <i>Rapid</i> Evaluation of Patients With Cancers: Real-World Evidence.

JCO oncology practice·2026
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Physicians' experiences with BRCA1/2 testing in community settings.

Nancy L Keating1, Kathryn A Stoeckert, Meredith M Regan

  • 1Division of General Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. keating@hcp.med.harvard.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|November 13, 2008
PubMed
Summary
This summary is machine-generated.

Community physicians effectively use BRCA1/2 genetic testing. However, recommendations for cancer risk management, like prophylactic mastectomy, vary by physician specialty and region.

More Related Videos

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Related Experiment Videos

Last Updated: Jun 28, 2026

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Area of Science:

  • Oncology
  • Genetics
  • Public Health

Background:

  • BRCA1/2 genetic testing is crucial for hereditary breast and ovarian cancer risk assessment.
  • Understanding nonacademic physicians' implementation of genetic testing and management recommendations is essential for patient care.
  • Variations in clinical practice can impact patient outcomes and access to appropriate cancer risk management strategies.

Purpose of the Study:

  • To assess the implementation of BRCA1/2 genetic testing by nonacademic physicians.
  • To evaluate physicians' recommendations for surveillance and cancer risk management in women with positive BRCA1/2 test results.
  • To identify factors influencing genetic counseling completeness and cancer risk management decisions.

Main Methods:

  • A national survey of 611 nonacademic physicians who ordered BRCA1/2 testing between 2004-2005.
  • Descriptive analysis of physicians' experiences with genetic testing.
  • Multivariable regression models to identify factors associated with comprehensive counseling and risk management recommendations.

Main Results:

  • Most physicians (68.2%) discussed key counseling items before testing.
  • Assistance from genetic counselors, longer counseling duration, and medical oncology specialty were associated with more complete counseling.
  • 61.4% of physicians recommended bilateral prophylactic mastectomy for a BRCA1 carrier; recommendations varied by specialty and geographic region.

Conclusions:

  • Nonacademic physicians are integrating BRCA1/2 testing into practice.
  • Surveillance recommendations align with guidelines, but prophylactic procedure recommendations (e.g., mastectomy) show variability.
  • Physician characteristics and practice setting influence cancer risk management recommendations, potentially affecting patient treatment choices.